Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 32Hodgkin Disease 29Lymphoma 10Sarcoma 7Uveal Melanoma 5Neoplasm Metastasis 4Neoplasms 3Leiomyosarcoma 2HIV Infections 2Solitary Fibrous Tumors 1Solid Tumor 1Skin Neoplasms 1Sarcoma, Synovial 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Neuroblastoma 1Lymphoma, T-Cell, Peripheral 1Immunotherapy 1Hyperthermia 1Hematologic Diseases 1Carcinoma 1Advanced Melanoma 1Acquired Immunodeficiency Syndrome 1AIDS-Related Complex 1

Interventions

pembrolizumab 1Temozolomide 1Paclitaxel 1Dacarbazine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Melanoma × Dacarbazine × Clear all
NCT07310784 2026-05-12

A Phase II Trial of LM103 in Advanced Melanoma

Suzhou BlueHorse Therapeutics Co., Ltd.

Phase 2 Recruiting
92 enrolled
Dermatologic

Advanced Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡